Literature DB >> 9199549

To fire the train: a second malignant-hyperthermia gene.

K Hogan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9199549      PMCID： PMC1716108          DOI： 10.1086/515483

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN： 0002-9297            Impact factor:   11.025


× No keyword cloud information.
  22 in total

1.  Malignant hyperthermia in dogs.

Authors:  T E Nelson
Journal:  J Am Vet Med Assoc       Date:  1991-03-15       Impact factor: 1.936

2.  Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.

Authors:  N Monnier; V Procaccio; P Stieglitz; J Lunardi
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

3.  A new screening test for susceptibility to malignant hyperpyrexia.

Authors:  F R Ellis; D G Harriman
Journal:  Br J Anaesth       Date:  1973-06       Impact factor: 9.166

4.  Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized.

Authors:  P J Halsall; P A Cain; F R Ellis
Journal:  Br J Anaesth       Date:  1979-10       Impact factor: 9.166

5.  Metabolic error of muscle metabolism after recovery from malignant hyperthermia.

Authors:  W Kalow; B A Britt; M E Terreau; C Haist
Journal:  Lancet       Date:  1970-10-31       Impact factor: 79.321

6.  Effects of anti-triadin antibody on Ca2+ release from sarcoplasmic reticulum.

Authors:  N R Brandt; A H Caswell; J P Brunschwig; J J Kang; B Antoniu; N Ikemoto
Journal:  FEBS Lett       Date:  1992-03-24       Impact factor: 4.124

7.  The King syndrome: malignant hyperthermia, myopathy, and multiple anomalies.

Authors:  E W McPherson; C A Taylor
Journal:  Am J Med Genet       Date:  1981

Review 8.  The genetics of malignant hyperthermia.

Authors:  S P Ball; K J Johnson
Journal:  J Med Genet       Date:  1993-02       Impact factor: 6.318

9.  Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia.

Authors:  J Fujii; K Otsu; F Zorzato; S de Leon; V K Khanna; J E Weiler; P J O'Brien; D H MacLennan
Journal:  Science       Date:  1991-07-26       Impact factor: 47.728

10.  Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.

Authors:  D H MacLennan; C Duff; F Zorzato; J Fujii; M Phillips; R G Korneluk; W Frodis; B A Britt; R G Worton
Journal:  Nature       Date:  1990-02-08       Impact factor: 49.962
View more
  3 in total

1.  Screening for mutations in the RYR1 gene in families with malignant hyperthermia.

Authors:  Viviane P Muniz; Helga C A Silva; Ana Maria C Tsanaclis; Mariz Vainzof
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

2.  Genetic mutations associated with susceptibility to perioperative complications in a longitudinal biorepository with integrated genomic and electronic health records.

Authors:  Nicholas J Douville; Sachin Kheterpal; Milo Engoren; Michael Mathis; George A Mashour; Whitney E Hornsby; Cristen J Willer; Christopher B Douville
Journal:  Br J Anaesth       Date:  2020-09-03       Impact factor: 9.166

3.  PharmGKB summary: very important pharmacogene information for CACNA1S.

Authors:  Katrin Sangkuhl; Robert T Dirksen; Maria L Alvarellos; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2020-02       Impact factor: 2.000
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.